This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by McGuire, W. P. Search for Related Content PubMed PubMed Citation Articles by McGuire, W. P., III Social Bookmarking                            What's this?

Current Status of Taxane and Platinum-Based Chemotherapy in Ovarian Cancer

From the Oncology Service Line, Franklin Square Hospital, Baltimore, MD.

Address reprint requests to Oncology Service Line, Franklin Square Hospital, 9000 Franklin Square Drive, Baltimore, MD 21237; email: wmcguire52{at}aol.com.

Before 1993, the standard of care for the chemotherapeutic management of advanced ovarian cancer was cisplatin or carboplatin combined with a classic alkylating agent (typically cyclophosphamide). Studies in the 1990s have changed this standard to one of the platinum-containing agents combined with a taxane, paclitaxel, or docetaxel. This article reviews the pertinent studies regarding paclitaxel combined with cisplatin or carboplatin, discusses the remaining controversies surrounding how best to combine these agents, and provides opinions regarding the discordant outcomes noted in studies of the paclitaxel-platinum doublet. A separate article discusses the docetaxel-platinum doublet and how that might be considered an appropriate option for first-line therapy in patients with advanced, newly diagnosed ovarian cancer.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?